Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6B
This month’s €6B acquisition of the UK heavyweight GW Pharmaceuticals by Jazz Pharmaceuticals has been…
This month’s €6B acquisition of the UK heavyweight GW Pharmaceuticals by Jazz Pharmaceuticals has been…
A cannabinoid medication marketed by GW Pharmaceuticals for the treatment of severe forms of epilepsy…
GW Pharmaceuticals, a British biotech developing cannabinoid drugs, is on a high after a successful…
Update (26/06/2018): The FDA has approved GW Pharmaceutical's drug Epidiolex in two severe forms of epilepsy.…
One of GW Pharma's cannabinoid drugs for epilepsy has suffered a set back in a…
New data in The Lancet provides further support for GW Pharma's drug, Epidiolex, for the…
As the 2017 reports roll in, we're already turning our gaze to 2018. These are…
Now that we've got the bad news out of the way, we're here to spread…
GW Pharma might be about to join the likes of Genmab in the biotech blockbuster…
Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company's stock…
Last year was a doozy for biotech, but it was spectacular for GW Pharmaceuticals. Its…
GW Pharmaceuticals announced Phase II results for a cannabinoid drug combination with the potential to…